Literature DB >> 17511024

Genetics of hepatocellular carcinoma.

Andreas Teufel1, Frank Staib, Stephan Kanzler, Arndt Weinmann, Henning Schulze-Bergkamen, Peter-R Galle.   

Abstract

The completely assembled human genome has made it possible for modern medicine to step into an era rich in genetic information and high-throughput genomic analysis. These novel and readily available genetic resources and analytical tools may be the key to unravel the molecular basis of hepatocellular carcinoma (HCC). Moreover, since an efficient treatment for this disease is lacking, further understanding of the genetic background of HCC will be crucial in order to develop new therapies aimed at selected targets. We report on the current status and recent developments in HCC genetics. Special emphasis is given to the genetics and regulation of major signalling pathways involved in HCC such as p53, Wnt-signalling, TGFbeta, Ras, and Rb pathways. Furthermore, we describe the influence of chromosomal aberrations as well as of DNA methylation. Finally, we report on the rapidly developing field of genomic expression profiling in HCC, mainly by microarray analysis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17511024      PMCID: PMC4147134          DOI: 10.3748/wjg.v13.i16.2271

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  180 in total

1.  5-Aza-2'-deoxycytidine leads to down-regulation of aberrant p16INK4A RNA transcripts and restores the functional retinoblastoma protein pathway in hepatocellular carcinoma cell lines.

Authors:  S I Suh; H Y Pyun; J W Cho; W K Baek; J B Park; T Kwon; J W Park; M H Suh; D A Carson
Journal:  Cancer Lett       Date:  2000-11-10       Impact factor: 8.679

2.  Hepatitis C virus core protein binds to the cytoplasmic domain of tumor necrosis factor (TNF) receptor 1 and enhances TNF-induced apoptosis.

Authors:  N Zhu; A Khoshnan; R Schneider; M Matsumoto; G Dennert; C Ware; M M Lai
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

3.  Expression of mutant nuclear beta-catenin correlates with non-invasive hepatocellular carcinoma, absence of portal vein spread, and good prognosis.

Authors:  T L Mao; J S Chu; Y M Jeng; P L Lai; H C Hsu
Journal:  J Pathol       Date:  2001-01       Impact factor: 7.996

4.  Geographic variation of p53 mutational profile in nonmalignant human liver.

Authors:  F Aguilar; C C Harris; T Sun; M Hollstein; P Cerutti
Journal:  Science       Date:  1994-05-27       Impact factor: 47.728

5.  Specific gene-expression profiles of noncancerous liver tissue predict the risk for multicentric occurrence of hepatocellular carcinoma in hepatitis C virus-positive patients.

Authors:  Masahiro Okamoto; Tohru Utsunomiya; Shigeki Wakiyama; Masaji Hashimoto; Kengo Fukuzawa; Takahiro Ezaki; Taizo Hanai; Hiroshi Inoue; Masaki Mori
Journal:  Ann Surg Oncol       Date:  2006-05-23       Impact factor: 5.344

Review 6.  TP53 and liver carcinogenesis.

Authors:  Frank Staib; S Perwez Hussain; Lorne J Hofseth; Xin W Wang; Curtis C Harris
Journal:  Hum Mutat       Date:  2003-03       Impact factor: 4.878

Review 7.  Wnt/beta-catenin signaling pathway as a novel cancer drug target.

Authors:  Hue H Luu; Ruiwen Zhang; Rex C Haydon; Elizabeth Rayburn; Quan Kang; Weike Si; Jong Kyung Park; Hui Wang; Ying Peng; Wei Jiang; Tong-Chuan He
Journal:  Curr Cancer Drug Targets       Date:  2004-12       Impact factor: 3.428

8.  Microarray profiling of the effects of histone deacetylase inhibitors on gene expression in cancer cell lines.

Authors:  S G Gray; C-N Qian; K Furge; X Guo; B T Teh
Journal:  Int J Oncol       Date:  2004-04       Impact factor: 5.650

9.  The region of the HPV E7 oncoprotein homologous to adenovirus E1a and Sv40 large T antigen contains separate domains for Rb binding and casein kinase II phosphorylation.

Authors:  M S Barbosa; C Edmonds; C Fisher; J T Schiller; D R Lowy; K H Vousden
Journal:  EMBO J       Date:  1990-01       Impact factor: 11.598

10.  Functional interaction between the HCMV IE2 transactivator and the retinoblastoma protein.

Authors:  C Hagemeier; R Caswell; G Hayhurst; J Sinclair; T Kouzarides
Journal:  EMBO J       Date:  1994-06-15       Impact factor: 11.598

View more
  52 in total

1.  From chronic liver disorders to hepatocellular carcinoma: Molecular and genetic pathways.

Authors:  Enzo Ierardi; Rosa Rosania; Mariangela Zotti; Floriana Giorgio; Simonetta Prencipe; Nicola Della Valle; Vincenzo De Francesco; Carmine Panella
Journal:  World J Gastrointest Oncol       Date:  2010-06-15

2.  Growth arrest-specific homeobox is associated with poor survival in patients with hepatocellular carcinoma.

Authors:  Peng Zhou; Zhi Chen; Rui-Min Chang; Wei Jiang; Lie-Lin Wu; Zhi-Ming Wang
Journal:  Med Oncol       Date:  2012-05-27       Impact factor: 3.064

3.  Expression and functional role of a transcribed noncoding RNA with an ultraconserved element in hepatocellular carcinoma.

Authors:  Chiara Braconi; Nicola Valeri; Takayuki Kogure; Pierluigi Gasparini; Nianyuan Huang; Gerard J Nuovo; Luigi Terracciano; Carlo M Croce; Tushar Patel
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-27       Impact factor: 11.205

Review 4.  AEG-1/MTDH/LYRIC in liver cancer.

Authors:  Devanand Sarkar
Journal:  Adv Cancer Res       Date:  2013       Impact factor: 6.242

5.  Mitogen-activated protein kinase kinase 1/2 inhibitors and 17-allylamino-17-demethoxygeldanamycin synergize to kill human gastrointestinal tumor cells in vitro via suppression of c-FLIP-s levels and activation of CD95.

Authors:  Margaret A Park; Guo Zhang; Clint Mitchell; Mohamed Rahmani; Hossein Hamed; Michael P Hagan; Adly Yacoub; David T Curiel; Paul B Fisher; Steven Grant; Paul Dent
Journal:  Mol Cancer Ther       Date:  2008-09       Impact factor: 6.261

6.  Liver insulin-like growth factor 2 methylation in hepatitis C virus cirrhosis and further occurrence of hepatocellular carcinoma.

Authors:  Philippe Couvert; Alain Carrié; Jacques Pariès; Jenny Vaysse; Audrey Miroglio; Antoine Kerjean; Pierre Nahon; Jamel Chelly; Jean-Claude Trinchet; Michel Beaugrand; Nathalie Ganne-Carrié
Journal:  World J Gastroenterol       Date:  2008-09-21       Impact factor: 5.742

7.  miR-301a is a candidate oncogene that targets the homeobox gene Gax in human hepatocellular carcinoma.

Authors:  Peng Zhou; Wei Jiang; Lielin Wu; Ruimin Chang; Kemin Wu; Zhiming Wang
Journal:  Dig Dis Sci       Date:  2012-02-29       Impact factor: 3.199

Review 8.  Hepatitis C-associated liver carcinogenesis: role of PML nuclear bodies.

Authors:  Kerstin Herzer; Guido Gerken; Thomas G Hofmann
Journal:  World J Gastroenterol       Date:  2014-09-21       Impact factor: 5.742

9.  Library of molecular associations: curating the complex molecular basis of liver diseases.

Authors:  Stefan Buchkremer; Jasmin Hendel; Markus Krupp; Arndt Weinmann; Kai Schlamp; Thorsten Maass; Frank Staib; Peter R Galle; Andreas Teufel
Journal:  BMC Genomics       Date:  2010-03-20       Impact factor: 3.969

Review 10.  Activins and activin antagonists in hepatocellular carcinoma.

Authors:  Alev Deli; Emanuel Kreidl; Stefan Santifaller; Barbara Trotter; Katja Seir; Walter Berger; Rolf Schulte-Hermann; Chantal Rodgarkia-Dara; Michael Grusch
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.